Annual CFO
-$70.24 M
+$37.90 M+35.05%
31 December 2023
Summary:
Protagonist Therapeutics annual cash flow from operations is currently -$70.24 million, with the most recent change of +$37.90 million (+35.05%) on 31 December 2023. During the last 3 years, it has risen by +$2.25 million (+3.10%). PTGX annual CFO is now -1913.95% below its all-time high of $3.87 million, reached on 31 December 2017.PTGX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$27.86 M
-$296.49 M-110.37%
30 September 2024
Summary:
Protagonist Therapeutics quarterly cash flow from operations is currently -$27.86 million, with the most recent change of -$296.49 million (-110.37%) on 30 September 2024. Over the past year, it has dropped by -$1.25 million (-4.70%). PTGX quarterly CFO is now -110.37% below its all-time high of $268.62 million, reached on 30 June 2024.PTGX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
$230.29 M
-$1.25 M-0.54%
30 September 2024
Summary:
Protagonist Therapeutics TTM cash flow from operations is currently $230.29 million, with the most recent change of -$1.25 million (-0.54%) on 30 September 2024. Over the past year, it has increased by +$349.12 million (+293.80%). PTGX TTM CFO is now -0.54% below its all-time high of $231.54 million, reached on 30 June 2024.PTGX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PTGX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +35.0% | -4.7% | +293.8% |
| 3 y3 years | +3.1% | +2.1% | +330.8% |
| 5 y5 years | -40.6% | -95.6% | +716.2% |
PTGX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +35.0% | -110.4% | +26.0% | -0.5% | +293.8% |
| 5 y | 5 years | -69.1% | +35.0% | -110.4% | +26.0% | -0.5% | +293.8% |
| alltime | all time | -1914.0% | +35.0% | -110.4% | +26.0% | -0.5% | +293.8% |
Protagonist Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$27.86 M(-110.4%) | $230.29 M(-0.5%) |
| June 2024 | - | $268.62 M(-1079.3%) | $231.54 M(-465.7%) |
| Mar 2024 | - | -$27.43 M(-261.7%) | -$63.32 M(-9.8%) |
| Dec 2023 | -$70.24 M(-35.0%) | $16.96 M(-163.7%) | -$70.24 M(-40.9%) |
| Sept 2023 | - | -$26.61 M(+1.4%) | -$118.83 M(+1.2%) |
| June 2023 | - | -$26.24 M(-23.6%) | -$117.42 M(+12.0%) |
| Mar 2023 | - | -$34.35 M(+8.6%) | -$104.82 M(-3.1%) |
| Dec 2022 | -$108.14 M(+0.3%) | -$31.64 M(+25.5%) | -$108.14 M(+4.5%) |
| Sept 2022 | - | -$25.20 M(+84.8%) | -$103.44 M(-3.1%) |
| June 2022 | - | -$13.63 M(-63.8%) | -$106.71 M(-8.6%) |
| Mar 2022 | - | -$37.67 M(+39.8%) | -$116.78 M(+8.3%) |
| Dec 2021 | -$107.86 M(+48.8%) | -$26.94 M(-5.4%) | -$107.86 M(+8.1%) |
| Sept 2021 | - | -$28.47 M(+20.1%) | -$99.79 M(+13.9%) |
| June 2021 | - | -$23.70 M(-17.6%) | -$87.61 M(+2.6%) |
| Mar 2021 | - | -$28.76 M(+52.4%) | -$85.39 M(+17.8%) |
| Dec 2020 | -$72.48 M(+74.5%) | -$18.87 M(+15.8%) | -$72.48 M(+6.7%) |
| Sept 2020 | - | -$16.29 M(-24.2%) | -$67.91 M(+3.1%) |
| June 2020 | - | -$21.48 M(+35.6%) | -$65.86 M(+61.8%) |
| Mar 2020 | - | -$15.85 M(+10.9%) | -$40.71 M(-2.0%) |
| Dec 2019 | -$41.53 M | -$14.29 M(+0.3%) | -$41.53 M(+11.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | -$14.25 M(-488.2%) | -$37.37 M(+15.3%) |
| June 2019 | - | $3.67 M(-122.0%) | -$32.40 M(-37.0%) |
| Mar 2019 | - | -$16.66 M(+64.4%) | -$51.47 M(+3.1%) |
| Dec 2018 | -$49.95 M(-1390.0%) | -$10.13 M(+9.3%) | -$49.95 M(-7.4%) |
| Sept 2018 | - | -$9.28 M(-39.8%) | -$53.96 M(+1255.5%) |
| June 2018 | - | -$15.40 M(+1.7%) | -$3.98 M(+337.5%) |
| Mar 2018 | - | -$15.14 M(+7.0%) | -$910.00 K(-123.5%) |
| Dec 2017 | $3.87 M(-112.9%) | -$14.15 M(-134.8%) | $3.87 M(-53.6%) |
| Sept 2017 | - | $40.70 M(-430.2%) | $8.34 M(-121.2%) |
| June 2017 | - | -$12.33 M(+19.0%) | -$39.34 M(+12.1%) |
| Mar 2017 | - | -$10.36 M(+7.0%) | -$35.09 M(+17.1%) |
| Dec 2016 | -$29.97 M(+108.4%) | -$9.68 M(+38.7%) | -$29.97 M(+19.7%) |
| Sept 2016 | - | -$6.98 M(-13.5%) | -$25.03 M(+14.7%) |
| June 2016 | - | -$8.07 M(+54.1%) | -$21.82 M(+26.9%) |
| Mar 2016 | - | -$5.24 M(+10.6%) | -$17.19 M(+19.5%) |
| Dec 2015 | -$14.38 M(+85.8%) | -$4.74 M(+25.7%) | -$14.38 M(+49.1%) |
| Sept 2015 | - | -$3.77 M(+9.4%) | -$9.65 M(+64.1%) |
| June 2015 | - | -$3.44 M(+41.6%) | -$5.88 M(+141.6%) |
| Mar 2015 | - | -$2.43 M | -$2.43 M |
| Dec 2014 | -$7.74 M | - | - |
FAQ
- What is Protagonist Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Protagonist Therapeutics?
- What is Protagonist Therapeutics annual CFO year-on-year change?
- What is Protagonist Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly CFO year-on-year change?
- What is Protagonist Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Protagonist Therapeutics?
- What is Protagonist Therapeutics TTM CFO year-on-year change?
What is Protagonist Therapeutics annual cash flow from operations?
The current annual CFO of PTGX is -$70.24 M
What is the all time high annual CFO for Protagonist Therapeutics?
Protagonist Therapeutics all-time high annual cash flow from operations is $3.87 M
What is Protagonist Therapeutics annual CFO year-on-year change?
Over the past year, PTGX annual cash flow from operations has changed by +$37.90 M (+35.05%)
What is Protagonist Therapeutics quarterly cash flow from operations?
The current quarterly CFO of PTGX is -$27.86 M
What is the all time high quarterly CFO for Protagonist Therapeutics?
Protagonist Therapeutics all-time high quarterly cash flow from operations is $268.62 M
What is Protagonist Therapeutics quarterly CFO year-on-year change?
Over the past year, PTGX quarterly cash flow from operations has changed by -$1.25 M (-4.70%)
What is Protagonist Therapeutics TTM cash flow from operations?
The current TTM CFO of PTGX is $230.29 M
What is the all time high TTM CFO for Protagonist Therapeutics?
Protagonist Therapeutics all-time high TTM cash flow from operations is $231.54 M
What is Protagonist Therapeutics TTM CFO year-on-year change?
Over the past year, PTGX TTM cash flow from operations has changed by +$349.12 M (+293.80%)